Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | HPGD | P15428 | 5/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.58 |
| ▸ | GAA | P10253 | 4/20 | 0.58 |
| ▸ | TSHR | P16473 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | CASP1 | P29466 | 3/20 | 0.58 |
| ▸ | CASP7 | P55210 | 3/20 | 0.58 |
| ▸ | GLA | P06280 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 4/20 | 0.54 |
| ▸ | MGAM | O43451 | 3/20 | 0.53 |
| ▸ | SI | P14410 | 2/20 | 0.53 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.53 |
| ▸ | CLK2 | P49760 | 2/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13016751 | 0.97 | MAOA (0.58) | ALDH1A1HPGDHSD17B10GAATSHR | |
| SCHEMBL7531522 | 0.84 | RXFP1 (0.60) | ALDH1A1HPGDHSD17B10GAATSHR | |
| SCHEMBL8229647 | 0.80 | ALDH1A1 (0.44) | ALDH1A1HPGDHSD17B10GAATSHR | |
| SCHEMBL14454479 | 0.78 | ALDH1A1 (0.50) | ALDH1A1HPGDHSD17B10GAATSHR | |
| SCHEMBL10790717 | 0.78 | ALDH1A1 (0.51) | ALDH1A1HPGDHSD17B10GAATSHR | |
| SCHEMBL7532870 | 0.77 | ALDH1A1 (0.50) | ALDH1A1HPGDHSD17B10GAATSHR | |
| SCHEMBL10795217 | 0.77 | CYP1A2 (0.53) | ALDH1A1HPGDHSD17B10GAATSHR | |
| SCHEMBL30591241 | 0.75 | MGAM (0.61) | ALDH1A1HPGDHSD17B10GAATSHR | |
| SCHEMBL274753 | 0.75 | ALDH1A1 (0.72) | ALDH1A1HPGDHSD17B10GAATSHR | |
| SCHEMBL10790197 | 0.75 | MAOA (0.51) | ALDH1A1HPGDHSD17B10GAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109293493-B | Novel benzhydryl compounds with mycobacterium tuberculosis inhibiting activity | 清华大学 | 2021-08-03 | — | — | CN | disclosed |
| US-20100324067-A1 | TETRACYCLIC DIPYRANO-COUMARIN COMPOUNDS WITH ANTI-HIV AND ANTI-MYCOBACTERIUM TUBERCULOSIS ACTIVITIES | INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2010-12-23 | — | — | US | disclosed |
| US-20100324067-A1 | TETRACYCLIC DIPYRANO-COUMARIN COMPOUNDS WITH ANTI-HIV AND ANTI-MYCOBACTERIUM TUBERCULOSIS ACTIVITIES | INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2010-12-23 | — | — | US | disclosed |
| EP-2216335-A1 | TETRIACYCLODIPYRANYL COUMARINS AND THE ANTI-HIV AND ANTI-TUBERCULOSIS USES THEREOF | Institute of Mataria Medica, Chinese Academy of Medical Sciences (CN) | 2010-08-11 | — | — | EP | disclosed |
| EP-1001774-B1 | USE OF PHOSPHOLAMBAN INHIBITORS FOR INCREASING CORONARY FLOW | ORION CORP (FI) | 2004-09-15 | — | — | EP | disclosed |
| US-6774103-B1 | Compounds for deactivating phospholamban function on Ca-ATPase (phospholamban inhibitors) | ORION CORPORATION (FI) | 2004-08-10 | — | — | US | disclosed |
| US-6538022-B1 | Three-dimensional structure of the cytosolic domain of phospholamban (PLB) and its active site from NMR data of sufficiently high resolution for the three-dimensional structure determination. rational drug design enabling the | ORION CORPORATION (FI) | 2003-03-25 | — | — | US | disclosed |
| EP-1039884-B1 | A METHOD FOR THE PREVENTION AND TREATMENT OF STUNNED MYOCARDIUM | ORION CORP (FI) | 2002-09-18 | — | — | EP | disclosed |
| WO-2002028183-A1 | FUNGICIDES | SYNGENTA LIMITED (GB) | 2002-04-11 | — | — | WO | disclosed |
| US-6265421-B1 | DILATATION OF ARTERIES | ORION CORPORATION (FI) | 2001-07-24 | — | — | US | disclosed |
| EP-1039884-A1 | A METHOD FOR THE PREVENTION AND TREATMENT OF STUNNED MYOCARDIUM | ORION CORPORATION (FI) | 2000-10-04 | — | — | EP | disclosed |
| EP-1017691-A1 | BISETHERS OF 1-OXA, AZA AND THIANAPHTHALEN-2-ONES AS PHOSPHOLAMBAN INHIBITORS | ORION CORPORATION (ORION-YHTYMA OY) (FI) | 2000-07-12 | — | — | EP | disclosed |
| EP-1001774-A1 | USE OF PHOSPHOLAMBAN INHIBITORS TO INCREASING CORONARY FLOW | ORION CORPORATION (FI) | 2000-05-24 | — | — | EP | disclosed |
| US-5968959-A | ADMINISTERING PHOSPHOLAMBAN INHIBITOR | ORION CORPORATION (FI) | 1999-10-19 | — | — | US | disclosed |
| WO-1999030696-A1 | A METHOD FOR THE PREVENTION AND TREATMENT OF STUNNED MYOCARDIUM | ORION CORPORATION (FI) | 1999-06-24 | — | — | WO | disclosed |
| WO-1999015523-A1 | BISETHERS OF 1-OXA, AZA AND THIANAPHTHALEN-2-ONES AS PHOSPHOLAMBAN INHIBITORS | ORION CORPORATION (FI) | 1999-04-01 | — | — | WO | disclosed |
| WO-1999000132-A1 | USE OF PHOSPHOLAMBAN INHIBITORS FOR INCREASING CORONARY FLOW | ORION CORPORATION (FI) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324067-A1 | TETRACYCLIC DIPYRANO-COUMARIN COMPOUNDS WITH ANTI-HIV AND ANTI-MYCOBACTERIUM TUBERCULOSIS ACTIVITIES | TBCB, TBC1D15, TBC1D5 | ALDH1A1 482/4885HPGD 1602/4885HSD17B10 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.